Entity Details

Primary name PPM1K_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ8N3J5
EntryNamePPM1K_HUMAN
FullNameProtein phosphatase 1K, mitochondrial
TaxID9606
Evidenceevidence at protein level
Length372
SequenceStatuscomplete
DateCreated2007-02-20
DateModified2021-06-02

Ontological Relatives

GenesPPM1K

GO terms

Show/Hide Table
GOName
GO:0005739 mitochondrion
GO:0005759 mitochondrial matrix
GO:0045764 positive regulation of cellular amino acid metabolic process
GO:0046872 metal ion binding
GO:0106306 protein serine phosphatase activity
GO:0106307 protein threonine phosphatase activity

Subcellular Location

Show/Hide Table
Subcellular Location
Mitochondrion matrix

Domains

Show/Hide Table
DomainNameCategoryType
IPR000222 PPM-type phosphatase, divalent cation bindingSiteBinding site
IPR001932 PPM-type phosphatase domainDomainDomain
IPR036457 PPM-type phosphatase domain superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
615135 OMIMMaple syrup urine disease, mild variant (MSUDMV)A mild form of maple syrup urine disease, a metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. MSUDMV is characterized by increased plasma levels of branched-chain amino acids (BCAA) apparent at birth. Treatment with a low-protein diet free of BCAA can result in normal psychomotor development and lack of metabolic episodes. The gene represented in this entry is involved in disease pathogenesis.